Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 4Biliary Tract Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Neuroendocrine Tumor Grade 3 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × surufatinib × Clear all
NCT03879057 2019-10-01

Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

Peking University

Phase 1 Unknown
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡